CASPR Lyo-CRISPR Assays for SARS-CoV-2 detection.

Innovative CRISPR-based solutions for diagnosis of COVID-19.


Our assays harness CASPR’s proprietary CRISPR-Cas12 enzyme, in a novel convenient lyophilized format, designed to detect SARS-CoV-2 RNA sequences present in clinical samples with sensitivity and specificity comparable to gold-standard technologies.

Features and Benefits

Sensitivity & Specificity

Compatible to qPCR

High troughtput and faster turnaround time

<60 minutes for processing 96 samples in parallel. 2 types of input (i) extracted RNA, (ii) Direct Sample

User Friendly

Lyophilized beads with minimal operator intervention

No specialized instruments

It requires just an incubator and CASPR FAM Box

CASPR Ly-CRISPR Assays are based on reverse transcription loop-mediated amplification (RT-LAMP) followed by fluorescence emission using a highly sensitive and specific CRISPR-Cas12 complex for the detection of different target regions in SARS-CoV-2.

Our simplified workflow is comprised of the following steps:

  • Sample Preparation: our assays have been validated with two different sample inputs:
    • Purified RNA: RNA can be purified using commercially available RNA purification kits
    • Direct from Sample: Directly from swabs without prior RNA purification
  • RT-LAMP: viral RNA from SARS-CoV-2 is reversed transcribed to cDNA and amplified using primers specifically designed to target a region in SARS-CoV-2 genomic RNA
  • CRISPR Reaction: In presence of multiple copies of the amplified DNA our proprietary CRISPR-Cas12, specifically configured to detect the target region, is activated and cleavages a reporter molecule causing fluorescence emission
  • Fluorescence Detection: Fluorescence readout is achieved in 5 minutes using our FAM Box, a portable and affordable device associated to a software that automatically interpret the results
Feature Direct from Sample Kit Purified RNA kit
FDA Submission EUA202431 (in review)* EUA201639(in review)*
Sample type Upper-respiratory specimens Upper-respiratory specimens
Targets 2 regions in N gene and 1 region in orf1ab 1 region in N gene
Assay Controls Positive and extraction controls included
Analytical Sensitivity 25 copies/μl 7.5 copies/μl
Clinical Performance 97.87% sensitivity
100% specificity
100% specificity
100% specificity
Inclusivity 100% >99.5%
Specificity (Cross-Reactivity) No observed cross-reactivity
(tested in silico and wet)
Assay Time ~ 60 minutes
Format Lyophilized reagents
Size 48 tests
* Distributed in accordance with Section IV.C.2 of Policy for Coronavirus Disease-2019 Tests During the Public Health

Ordering information and Support


Caspr Lyo-CRISPR SARS-CoV-2 Kit

from Extracted RNA
(48 patients)


Direct Caspr Lyo-CRISPR SARS-CoV-2 Kit

directly from sample
(48 patients)



for portable and affordable fluorescence readout
Contact Technical Support